Epidermal growth factor receptor mutation-guided treatment for lung cancers: Where are we now?
Thorac Cancer
; 2(1): 1-6, 2011 Feb.
Article
em En
| MEDLINE
| ID: mdl-27755839
ABSTRACT
Epidermal growth factor receptor (EGFR) kinase domain mutations (from exon 18 to 21) alter the efficacy of the EGFR tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Lung cancer patients with drug-sensitive EGFR mutations initially respond, but acquire resistance after approximately one year of tyrosine kinase inhibitor treatment. This review summarizes EGFR gene mutation profiles for East Asian non-small-cell lung cancer patients according to recent publications. Strategies for the treatment of acquired resistance mediated by EGFR T790M are also reviewed.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Thorac Cancer
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Estados Unidos